Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Projected to Grow at 16.3% CAGR, Reaching $28.3 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry Market Size Be by 2025?
The market for glucagon-like peptide (glp)-1 agonists utilized for weight reduction has experienced swift expansion lately, projected to increase from a valuation of $13.38 billion in 2024 to $15.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.9%; this surge during the past period is attributable to several factors, including the escalating incidence of obesity, a higher number of type 2 diabetes diagnoses, heightened public consciousness regarding the health hazards linked to obesity, greater spending on healare, an intensified concentration on handling long-term illnesses, and enhanced availability of medical services.

What's the Long-Term Growth Forecast for the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Through 2029?
The market encompassing weight loss treatments utilizing glucagon-like peptide-1 (GLP-1) agonists is projected to experience swift expansion moving forward, reaching an estimated value of $28.3 billion by the year 2029, reflecting a compound annual growth rate (CAGR) of 16.3%. This anticipated surge in valuation throughout the projected timeframe stems from several key factors: a heightened need for successful methods to manage weight, the broadening of therapeutic applications for these medications beyond just diabetes treatment, greater capital being channeled into research endeavors, the increasing move toward individualized medical approaches, and heightened public consciousness driven by direct consumer promotion. Significant shifts expected to influence this sector during the forecast interval involve the creation of oral versions of GLP-1 drugs, progress in technologies designed for extended drug release, the incorporation of digital health technologies for patient oversight, the application of artificial intelligence in discovering and developing pharmaceuticals, and novel advancements in modifying peptides to boost how well they work.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Expansion?
The increasing incidence of obesity is anticipated to serve as a catalyst for the expansion of the market for glucagon-like peptide (GLP)-1 agonist medications designed for weight reduction in the upcoming period. Health concerns stemming from the excessive accumulation of body fat constitute the definition of obesity, which is a recognized medical state. This climbing rate of obesity is attributed to dietary patterns that favour high consumption of convenience foods and sweetened beverages over nutritionally sound and balanced meals. With a growing population grappling with obesity and its associated health issues, the need for successful therapeutic interventions escalates, consequently boosting the adoption of GLP-1 agonist weight loss pharmaceuticals due to their established efficacy in facilitating weight loss and improving metabolic functions. To illustrate this trend, data released by the World Health Organization, an international entity headquartered in Switzerland, indicated in March 2024 that in the year 2022, one out of every eight individuals worldwide experienced obesity; out of the 2.5 billion adults classified as overweight, roughly 890 million met the criteria for obesity, while globally, 43% of the adult population was overweight generally, with 16% being in the obese range. Consequently, this escalating global burden of obesity is fueling the expansion of the market for GLP-1 agonist weight loss pharmaceuticals.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp

What Are the Key Trends Driving Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth?
Leading corporations within the market for glucagon-like peptide (GLP)-1 agonist pharmaceuticals focused on weight reduction are actively creating novel approaches to combat obesity, aiming to boost effectiveness and elevate the results for patients. Therapies categorized as obesity treatment solutions function by emulating the actions of the GLP-1 hormone, which serves to control hunger signals, increase feelings of fullness, and consequently facilitate the shedding of weight. These pharmacological agents contribute to obesity management through the enhancement of metabolic processes while also aiding in sustained weight maintenance. A specific example illustrating this progress is the November 2023 sanction granted by the US Food and Drug Administration to Eli Lilly and Company, an American pharmaceutical firm, for their product Zepbound, which is prescribed for ongoing weight control in adults struggling with obesity or excess weight complicated by conditions like type 2 diabetes or sleep apnea. This particular medication achieves its effect by engaging both the GIP and GLP-1 hormone receptors, leading to a reduction in appetite and an improvement in metabolic performance.

How Is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmented?
The glucagon-like peptide (glp)-1 agonists weight loss drugsmarket covered in this report is segmented -

1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies

Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp

Which Companies Are Leading the Charge in Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Innovation?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.

Which Regions Are Leading the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market in Revenue?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24226

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.